The XBB.1.5 coronavirus disease 2019 (COVID-19) vaccine has emerged as a potential breakthrough in the fight against the ongoing pandemic. In a recent study conducted in the Netherlands, researchers evaluated the vaccine’s effectiveness in reducing hospitalizations and Intensive Care Unit (ICU) admissions among previously vaccinated adults aged 60 and over. This article explores the key findings of the study and highlights the significance of the XBB.1.5 vaccine in mitigating severe COVID-19 cases in older adults.
Background: The Seasonal COVID-19 Vaccination Campaign in the Netherlands
The Netherlands initiated its seasonal COVID-19 vaccination campaign in October 2023, with a focus on high-risk groups, including individuals aged 60 and older, healthcare workers, pregnant women, and those with underlying medical conditions. The XBB1.5 Comirnaty vaccine was administered to the targeted population, with personal vaccination invitations sent to residents aged 60 and above. By early December, approximately 42.9% of this demographic had received the vaccine, and the campaign is set to continue until the end of the month. However, further research is necessary to understand the long-term effectiveness and impact of the XBB.1.5 COVID-19 vaccine on hospitalization and ICU admission rates as more data becomes available post-December 2023.
Study Design and Methodology
To assess the effectiveness of the 2023 seasonal COVID-19 vaccination, researchers employed a screening method focusing on individuals aged 60 and older who had received at least one prior COVID-19 vaccination. The study analyzed hospitalization data from October 9 to December 5, 2023, sourced from the National Institute for Health and Care Excellence (NICE) COVID-19 database. Hospitalization records were linked to the national COVID-19 vaccination database (CIMS) to determine the vaccination status of the patients. The study utilized a logistic regression model to estimate vaccine effectiveness (VE) and its 95% confidence intervals.
Read: The Increased Risk of Arrhythmias Following COVID-19: What You Need to Know
Key Findings: XBB.1.5 Vaccine Effectiveness in Reducing Hospitalizations
The study analyzed a total of 2,050 hospitalizations among individuals aged 60 and above, of which 14.4% had received the XBB.1.5 COVID-19 vaccine for 2023. The findings revealed that the vaccine demonstrated a VE of approximately 70.7% (CI, 66.6 to 74.3) against hospitalization. Among the 92 cases of ICU admissions analyzed, the VE was estimated to be around 73.3% (CI 42.2 to 87.6). Notably, the VE for the age group of 60-74 was slightly lower (68.3%, CI: 58.3 to 75.9) compared to those aged 75 and above.
Impact of Age on Vaccine Effectiveness
The study observed a higher number of hospitalizations among individuals aged 75 and older compared to the 60-74 age group. However, the VE estimates for both age groups were relatively similar. This suggests that the XBB.1.5 vaccine offers substantial protection against severe COVID-19 outcomes for older adults, regardless of their age within the targeted demographic.
Comparison with Previous Vaccination Campaigns
Compared to the fall campaign of the previous year, the VE estimates for the 2023 seasonal COVID-19 vaccination were slightly higher for individuals aged 60-79. This indicates that the XBB.1.5 vaccine is more effective in reducing hospitalizations and ICU admissions in older adults, providing a positive outcome for the ongoing vaccination efforts.
Limitations of the Study
While the study provides valuable insights into the effectiveness of the XBB.1.5 COVID-19 vaccine, it is essential to consider its limitations. The analysis relied on the NICE hospitalization database, which may not capture all COVID-19 hospitalizations during the study period. Additionally, the study was unable to adjust for comorbidities, potentially leading to an underestimation of VE. The relatively early period of the campaign may have included frailer individuals, which could impact the vaccine’s effectiveness. Furthermore, the study’s reliance on hospitalization status at the time of admission may not have allowed sufficient time for the vaccine to prevent severe disease.
Future Implications and Further Research
Despite these limitations, the findings of the study highlight the encouraging effectiveness of the XBB.1.5 COVID-19 vaccine in reducing severe disease outcomes among older adults. As the seasonal vaccination campaign continues and more data becomes available, further research is needed to evaluate the long-term effectiveness and impact of the XBB.1.5 vaccine on hospitalizations and ICU admissions. This will contribute to a better understanding of the vaccine’s role in controlling the spread of COVID-19 and protecting vulnerable populations.
Conclusion
The XBB.1.5 COVID-19 vaccine has emerged as a game-changer in the fight against the ongoing pandemic. The study conducted in the Netherlands demonstrates the vaccine’s effectiveness in reducing hospitalizations and ICU admissions among older adults. With a VE of approximately 70.7% against hospitalization, the XBB.1.5 vaccine offers significant protection against severe COVID-19 outcomes. These findings underscore the importance of vaccination campaigns targeting high-risk groups and highlight the potential impact of vaccines in mitigating the burden on healthcare systems. As the vaccination efforts continue, it is crucial to closely monitor and evaluate the long-term effectiveness of the XBB.1.5 vaccine to inform future public health strategies.
Disclaimer: The information provided in this article is based on a preliminary scientific report and should not be regarded as conclusive or treated as established information. It is crucial to refer to peer-reviewed research and official health guidelines for comprehensive and up-to-date information on COVID-19 vaccines.
References:
- Preliminary scientific report. Henri van Werkhoven, Anne-Wil Valk, Bente Smagge, et al. Early COVID-19 vaccine effectiveness of XBB.1.5 vaccine against hospitalization and ICU admission, the Netherlands, 9 October – 5 December 2023, medRxiv, 2023, DOI- https://doi.org/10.1101/2023.12.12.23299855